Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

APC/CCdh1 regulates the balance between maintenance and differentiation of hematopoietic stem and progenitor cells.

Ewerth D, Kreutmair S, Schmidts A, Ihorst G, Follo M, Wider D, Felthaus J, Schüler J, Duyster J, Illert AL, Engelhardt M, Wäsch R.

Cell Mol Life Sci. 2019 Jan;76(2):369-380. doi: 10.1007/s00018-018-2952-3. Epub 2018 Oct 24.

PMID:
30357422
2.

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).

Waldschmidt JM, Keller A, Ihorst G, Grishina O, Müller S, Wider D, Frey AV, King K, Simon R, May A, Tassone P, Duyster J, Jung M, Raje N, Wäsch R, Engelhardt M.

Haematologica. 2018 Oct;103(10):e473-e479. doi: 10.3324/haematol.2018.189969. Epub 2018 Apr 19. No abstract available.

3.

Secreted dual reporter assay with Gaussia luciferase and the red fluorescent protein mCherry.

Wider D, Picard D.

PLoS One. 2017 Dec 8;12(12):e0189403. doi: 10.1371/journal.pone.0189403. eCollection 2017.

4.

CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.

Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M.

Br J Haematol. 2017 Oct;179(1):36-49. doi: 10.1111/bjh.14807. Epub 2017 Jul 2.

PMID:
28670693
5.

Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.

Schnerch D, Schüler J, Follo M, Felthaus J, Wider D, Klingner K, Greil C, Duyster J, Engelhardt M, Wäsch R.

Oncotarget. 2017 Mar 28;8(13):21153-21166. doi: 10.18632/oncotarget.15503.

6.

LSD1 engages a corepressor complex for the activation of the estrogen receptor α by estrogen and cAMP.

Bennesch MA, Segala G, Wider D, Picard D.

Nucleic Acids Res. 2016 Oct 14;44(18):8655-8670. Epub 2016 Jun 20.

7.

From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration.

Lorenz J, Waldschmidt J, Wider D, Follo M, Ihorst G, Chatterjee M, May AM, Duyster J, Rosenwald A, Wäsch R, Zirlik K, Engelhardt M.

Br J Haematol. 2016 Sep;174(6):985-9. doi: 10.1111/bjh.13825. Epub 2015 Oct 22. No abstract available.

PMID:
26491948
8.

Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.

Prasad S, Gaedicke S, Machein M, Mittler G, Braun F, Hettich M, Firat E, Klingner K, Schüler J, Wider D, Wäsch RM, Herold-Mende C, Elsässer-Beile U, Niedermann G.

Cancer Res. 2015 Jun 1;75(11):2166-76. doi: 10.1158/0008-5472.CAN-14-2415. Epub 2015 Apr 3.

9.

Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.

Schueler J, Wider D, Klingner K, Siegers GM, May AM, Wäsch R, Fiebig HH, Engelhardt M.

PLoS One. 2013 Nov 6;8(11):e79939. doi: 10.1371/journal.pone.0079939. eCollection 2013.

10.

Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.

Udi J, Schüler J, Wider D, Ihorst G, Catusse J, Waldschmidt J, Schnerch D, Follo M, Wäsch R, Engelhardt M.

Br J Haematol. 2013 Apr;161(1):104-16. doi: 10.1111/bjh.12226. Epub 2013 Feb 6.

PMID:
23384035
11.

Characterizing the mechanical parameters of forward and backward falls as experienced in snowboarding.

Schmitt KU, Wider D, Michel FI, Brügger O, Gerber H, Denoth J.

Sports Biomech. 2012 Mar;11(1):57-72.

PMID:
22518945
12.

Early and mature endothelial progenitors and VEGFR2+-cells in multiple myeloma: association with disease characteristics and variation in different cell compartments.

Udi J, Wider D, Kleber M, Ihorst G, Müller A, Wäsch R, Engelhardt M.

Leuk Res. 2011 Sep;35(9):1265-8. doi: 10.1016/j.leukres.2011.05.021.

PMID:
21684596
13.

Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.

Ngo BT, Felthaus J, Hein M, Follo M, Wider D, Ihorst G, Engelhardt M, Wäsch R.

Leuk Lymphoma. 2010 Sep;51(9):1632-42. doi: 10.3109/10428194.2010.496014.

PMID:
20578819
14.

The complementation of yeast with human or Plasmodium falciparum Hsp90 confers differential inhibitor sensitivities.

Wider D, Péli-Gulli MP, Briand PA, Tatu U, Picard D.

Mol Biochem Parasitol. 2009 Apr;164(2):147-52.

PMID:
19320098
15.

Characterization of in vitro growth of multiple myeloma cells.

Zlei M, Egert S, Wider D, Ihorst G, Wäsch R, Engelhardt M.

Exp Hematol. 2007 Oct;35(10):1550-61.

PMID:
17889722
16.

Effects of 5-aza-2'-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells.

Guo Y, Engelhardt M, Wider D, Abdelkarim M, Lübbert M.

Leukemia. 2006 Jan;20(1):115-21.

PMID:
16307025
17.

Generation of antigen-presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients.

Fisch P, Köhler G, Garbe A, Herbst B, Wider D, Kohler H, Schaefer HE, Mertelsmann R, Brugger W, Kanz L.

Eur J Immunol. 1996 Mar;26(3):595-600.

PMID:
8605926

Supplemental Content

Support Center